Spanish biotechnology firm Aelix Therapeutics has commenced patient enrolment in a Phase I clinical trial (AELIX-002) of HTI vaccine to treat patients infected with HIV.

Designed by the firm’s chief scientific officer Dr Christian Brander and colleagues, HTI vaccine immunogen combines specific HIV regions that are enriched with T-cell responses in individuals who can control the virus without antiretroviral drugs.

The randomised, double-blind, placebo-controlled Phase I AELIX-002 will evaluate the safety, tolerability and immunogenicity of the vaccine.

To enhance the immune responses to HIV, the vaccine will be given in a prime-boost regimen, including an initial DNA vector and a subsequent Modified Vaccinia Ankara virus (MVA) vector.

Aelix Therapeutics chief medical officer Dr Ian McGowan said: “Developing a safe and effective therapeutic HIV vaccine that frees patients from the burden of antiretroviral therapy could be considered as the final frontier in HIV research.”

"Developing a safe and effective therapeutic HIV vaccine that frees patients from the burden of antiretroviral therapy could be considered as the final frontier in HIV research."

Intended to optimise the expansion of immune responses associated with the vaccine, the trial’s enrolment will include patients who were diagnosed less than six months after their initial HIV infection and immediately treated using antiretroviral therapy (ART).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial is being conducted at the University Hospital Germans Trias i Pujol (HUGTIP) in Badalona, Spain, and will be led by investigators from the IrsiCaixa AIDS Research Institute and the Fight AIDS Foundation.

Trial’s HUGTIP principal investigator Dr Beatriz Mothe said: “The vaccine has been designed with the goal of refocusing patients' immune response to especially vulnerable sites of HIV so that they can control their HIV infection without further antiretroviral therapy.”

Results from the Phase I trial for HTI vaccine are expected to be reported next year.